Applying a matrix approach for potency assay development for in vivo and ex vivo gene therapies
Broadcast date
Mon, Mar 14, 2022
Presented by
- Dominic Hildebrand - BayerShihua Lin - AstraZeneca
Quick Description
The webinar aims to bring an awareness of the challenges associated with developing potency assays that adequately reflect the mechanism of action (MoA) of gene therapies (GTs). ​
Details
The webinar aims to bring an awareness of the challenges associated with developing potency assays that adequately reflect the mechanism of action (MoA) of gene therapies (GTs). ​
Understanding MoA for GTs is complex where more than one function is critical to the therapeutic activity; targeting a single attribute for the potency assay is not sufficient. A matrix approach is proposed with examples provided to demonstrate this potency assay development strategy in practice for in vivo and ex vivo GTs.Â
Proposed solutions to overcome challenges often associated with reference standards and assay controls for potency assays are also offered.
Q&A panelists
- Roland Pach – Associate Director, Roche
- Christina Grigoriadou – Associate Director, AstraZeneca
- Win Den Cheung – Director, Analytical Development, REGENXBIO
Speakers
Dominic Hildebrand
Head of Laboratory, Analytical Development and Quality Control
Bayer
Shihua Lin
Director
AstraZeneca